Assessment of rationality of available fixed dose combinations of antibiotics in India

References

• Antimicrobial resistance. WHO Fact Sheet. 2020 cited 2021 Jan 02. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
   Google Scholar
• Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017 Dec 21;12(12):e0189621.
   PubMed Web of Science ®Google Scholar
• Pokharel S, Raut S, Adhikari B. Tackling antimicrobial resistance in low-income and middle-income countries. BMJ Glob Health. 2019 Nov 10;4(6):e002104.
   PubMed Web of Science ®Google Scholar
• National action plan on AMR (NAP-AMR) 2017-2021. 2017 [cited 2021 Jan 02].https://cdn.cseindia.org/userfiles/NAP-AMR.pdf
   Google Scholar
• McGettigan P, Roderick P, Mahajan R, et al. Use of Fixed Dose Combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or psychotropic drugs. PLoS Med. 2015 May 12;12(5):e1001826.
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Agrawal S, Ashokraj Y, et al. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):703–721.
   PubMedGoogle Scholar
• Valenti WM. Expanding role of co formulations in the treatment of HIV infection: impact of fixed-dose combinations. AIDS Read. 2004 Oct;14(10):541–3, 547–50.
   Google Scholar
• Beeson JG, Boeuf P, Fowkes FJ. Maximizing antimalarial efficacy and the importance of dosing strategies. BMC Med. 2015 May 9;13: 110.
   PubMed Web of Science ®Google Scholar
• Bortone B, Jackson C, Hsia Y, et al. High global consumption of potentially inappropriate fixed dose combination antibiotics: analysis of data from 75 countries. PLoS ONE. 2021;16(1):e0241899.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Roderick P, Mahajan R, et al. Use of fixed dose combination (FDC) drugs in India: central regulatory approval and sales of FDCs containing non-steroidal anti-inflammatory drugs (NSAIDs), metformin, or psychotropic drugs. PLoS Med. 2015;12:e1001826.
   PubMed Web of Science ®Google Scholar
• Shafiq N, Kumar G, Gautam V, et al. Fixed-dose combinations of antimicrobials: a need for special attention. Indian J Med Microbiol. 2016 Apr-Jun;34(2):208–209.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Khan UM, Balkrishnan R. Fixed-dose combination antibiotics in India: global perspectives. Lancet. 2016;21(4):e521.
   Google Scholar
• Palwe S, Veeraraghavan B, Periasamy H, et al. Unorthodox Parenteral β-Lactam and β-Lactamase inhibitor combinations: flouting Antimicrobial Stewardship and compromising patient care. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00168–20 .
   PubMed Web of Science ®Google Scholar
• McGettigan P, Roderick P, Kadam A, et al. Threats to global antimicrobial resistance control: centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2019 Jan;85(1):59–70.
   PubMed Web of Science ®Google Scholar
• Sayer B, Bortone B, Sharland M, et al. Fixed‐dose combination antibiotics: the search for evidence using the example of ampicillin–cloxacillin. Br J Clin Pharmacol. 2021 Jan 11;87:2996–2999.
   PubMed Web of Science ®Google Scholar
• New drugs approved by CDSCO; 2021 cited 2021 Jan 05. https://www.cdscoonline.gov.in/CDSCO/Drugs
   Google Scholar
• FDA approved drugs. 2021 cited 2021 Jan 05. https://www.accessdata.fda.gov/scripts/cder/daf
   Google Scholar
• WHO model List of Essential Medicines. 2019 cited 2021 Jan 05. https://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06
   Google Scholar
• List of banned drugs. 2018 cited 2021 Jan 05. https://cdsco.gov.in/opencms/opencms/en/consumer/List-Of-Banned-Drugs
   Google Scholar
• Brunton LL, Chabner BA, Knollmann BC. Goodman and Gilman’s The Pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill Medical; 2017.
   Google Scholar
• Bennet JE, Dolin R, Blaser MJ. Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier; 2020.
   Google Scholar
• Britto CD, John J, Verghese VP, et al. A systematic review of antimicrobial resistance of typhoidal Salmonella in India. Indian J Med Res. 2019 Feb;149(2):151–163.
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma SK, Singh BK, et al. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India. Indian J Med Res. 2019 Jan;149(1):62–66.
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, Liu J, O’Donnell JN, et al. Prolonged infusion Piperacillin-Tazobactam decreases mortality and improves outcomes in severely Ill patients: results of a systematic review and meta-analysis. Crit Care Med. 2018 Feb;46(2):236–243.
   PubMed Web of Science ®Google Scholar
• Sharland M, Gandra S, Huttner B, et al. EML Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 essential medicines list becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019 Dec;19(12):1278–1280. PMID: 31782385 .
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018 Mar;18(3):285–295.
   PubMed Web of Science ®Google Scholar
• Rawat D, Hasan AS, Capoor MR, et al. In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria. Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):131–139.
   PubMed Web of Science ®Google Scholar
• Tong W, Wang R, Chai D, et al. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp. Int J Antimicrob Agents. 2006 Nov;28(5):454–456.
   PubMed Web of Science ®Google Scholar
• Abodakpi H, Wanger A, Tam VH. Know about PK/PD in the era of emerging multidrug-resistance: beta-Lactam/Beta-Lactamase inhibitor combinations. Clin Lab Med. 2019 September;39(3):473–485.
   PubMed Web of Science ®Google Scholar
• Crass RL, Pai MP. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors. Pharmacotherapy. 2019 Feb;39(2):182–195.
   PubMed Web of Science ®Google Scholar
• Monogue ML, Nicolau DP. Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?. Expert Rev Anti Infect Ther. 2019 Aug;17(8):571–582.
   PubMed Web of Science ®Google Scholar
• Xiao AJ, Miller BW, Huntington JA, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016 Jan;56(1):56–66.
   PubMed Web of Science ®Google Scholar
• Policy guidelines for approval of Fixed Dose Combinations in India; 2013 cited 2021 Jan 05. https://main.mohfw.gov.in/sites/default/files/6404452866Kokate%20Report.pdf
   Google Scholar
• Guo Q, Goldenberg JZ, Humphrey C, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019 Apr 30;4(4). CD004827 . DOI: https://doi.org/10.1002/14651858.CD004827.pub5.
   Google Scholar
• Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2015 Nov-Dec;49(Suppl 1):S37–45.
   PubMed Web of Science ®Google Scholar
• Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017 Dec 19;12(12):CD006095. DOI:https://doi.org/10.1002/14651858.CD006095.pub4
   PubMed Web of Science ®Google Scholar
• Verma SB, Vasani R. Male genital dermatophytosis - clinical features and the effects of the misuse of topical steroids and steroid combinations - an alarming problem in India. Mycoses. 2016 Oct;59(10):606–614 .
   PubMed Web of Science ®Google Scholar
• Singh H, Mohan P, Kumar R, et al. Difference in described indications of medicines among drug information sources in India: an issue urgently to be addressed. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):93–97.
   PubMedGoogle Scholar